Delivery Order SPE2DB22D9353-SPE2DB25FX2AV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,330.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra 30 mg/ml syringes. The contract is classified as a firm fixed-price delivery order with an ultimate completion date of July 23, 2025, and was executed on July 22, 2025. This award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits within the broader...
- The Defense Logistics Agency has awarded a delivery order valued at $2,275.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. This firm fixed-price delivery order, issued on July 24, 2025, with an ultimate completion date of August 14, 2025, is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $7,330.50 on July 22, 2025, for the supply of Fasenra 30 mg/ml syringes. The contract, with an ultimate completion date of July 23, 2025, was issued without a set-aside designation and funded by the Defense Logistics Agency's Medical Supply Chain division. This delivery order is issued under DMS Pharmaceutical Group's...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,443.50 firm fixed-price contract is for the supply of Fasenra 30mg/mL syringe, a biologic drug used to treat severe asthma. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, that allows the agency to issue delivery orders for a...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $24,435.00, is for the delivery of Fasenra 30 mg/ml syringes and does not have a set-aside designation. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a wide range of branded and generic prescription drugs,...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $7,330.50, is for the delivery of Fasenra 30 mg/mL syringes. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to issue firm fixed-price...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,330.50 contract is for the supply of Fasenra 30 mg/ml syringes, a biologic medication used to treat severe asthma. The award is part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency Troop Support Medical to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,443.50 order is for the provision of Fasenra 30 mg/mL syringes, with a period of performance through January 31, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with the Defense Logistics Agency,...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $12,217.50 contract is for the provision of Fasenra 30 mg/mL syringes, a specialty pharmaceutical product. The delivery order was issued under a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, which enables the agency to place orders for a wide range of...
- This firm fixed-price delivery order worth $2,443.50 was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of FASENRA 30 MG/ML SYRINGEML, a specialty medication, with a completion date of September 9, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB25FX2AVDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $19,548.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra 30 mg/ml syringes. The award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and carries no set-aside designation. DMS Pharmaceutical Group is performing under its existing single-award Indefinite Delivery Contract with DLA's SPE2DB program, a comprehensive pharmaceutical supply vehicle valued at $499,999,999 and valid through November 2026, which enables the agency to issue delivery orders for a wide range of pharmaceutical products supporting military health facilities. Fasenra (benralizumab) is a biologic medication used in the treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. As a key supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group leverages its woman-owned small business status and extensive portfolio of branded and generic prescription drugs, biologics, and medical consumables to serve Department of Defense healthcare systems. The company's consistent performance under the DLA SPE2DB program demonstrates its critical role in ensuring timely delivery of specialized pharmaceutical products to military medical facilities nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.5k | 7/31/25 |